Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

David K. Durnick, Mark E. Law, Matthew J. Maurer, Yasodha Natkunam, Ronald Levy, Izidore S. Lossos, Paul J. Kurtin, Ellen McPhail

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalAmerican Journal of Clinical Pathology
Volume134
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Germinal Center
Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Gene Expression Profiling
Phenotype
Immunophenotyping
Fluorescence In Situ Hybridization
Proteins

Keywords

  • BCL6
  • Diffuse large B-cell lymphoma
  • LMO2
  • t(14;18)IgH/BCL2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. / Durnick, David K.; Law, Mark E.; Maurer, Matthew J.; Natkunam, Yasodha; Levy, Ronald; Lossos, Izidore S.; Kurtin, Paul J.; McPhail, Ellen.

In: American Journal of Clinical Pathology, Vol. 134, No. 2, 08.2010, p. 278-281.

Research output: Contribution to journalArticle

Durnick, David K. ; Law, Mark E. ; Maurer, Matthew J. ; Natkunam, Yasodha ; Levy, Ronald ; Lossos, Izidore S. ; Kurtin, Paul J. ; McPhail, Ellen. / Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. In: American Journal of Clinical Pathology. 2010 ; Vol. 134, No. 2. pp. 278-281.
@article{4d0ba101cdd046f5938f94478ecc6f4f,
title = "Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma",
abstract = "Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.",
keywords = "BCL6, Diffuse large B-cell lymphoma, LMO2, t(14;18)IgH/BCL2",
author = "Durnick, {David K.} and Law, {Mark E.} and Maurer, {Matthew J.} and Yasodha Natkunam and Ronald Levy and Lossos, {Izidore S.} and Kurtin, {Paul J.} and Ellen McPhail",
year = "2010",
month = "8",
doi = "10.1309/AJCPATUP1D0HGCUG",
language = "English (US)",
volume = "134",
pages = "278--281",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

AU - Durnick, David K.

AU - Law, Mark E.

AU - Maurer, Matthew J.

AU - Natkunam, Yasodha

AU - Levy, Ronald

AU - Lossos, Izidore S.

AU - Kurtin, Paul J.

AU - McPhail, Ellen

PY - 2010/8

Y1 - 2010/8

N2 - Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.

AB - Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.

KW - BCL6

KW - Diffuse large B-cell lymphoma

KW - LMO2

KW - t(14;18)IgH/BCL2

UR - http://www.scopus.com/inward/record.url?scp=77955621172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955621172&partnerID=8YFLogxK

U2 - 10.1309/AJCPATUP1D0HGCUG

DO - 10.1309/AJCPATUP1D0HGCUG

M3 - Article

C2 - 20660332

AN - SCOPUS:77955621172

VL - 134

SP - 278

EP - 281

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -